SCOTUS will not hear $1.2 billion written description appeal, despite landmark enablement review
The court rejected Juno Therapeutics’ appeal, despite claims of similarity with Amgen v Sanofi dispute
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.